Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Survival and disease complications in thalassemia major.Ann N Y Acad Sci. 1998; 850: 227-231
- Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance.J Cardiovasc Magn Reson. 2008; 10: 42
- Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis.Br J Haematol. 2020; 191: 897-905
- Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.J Paediatr Child Health. 2011; 47: 535-540
- Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.Transfusion. 2007; 47: 1919-1929
- Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.Blood. 2012; 119 (Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't): 2746-2753
- Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.Aust N Z J Med. 1993; 23: 656-661
- Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.Br J Haematol. 1992; 82: 431-436
- Cardiac events and cardiac T2∗ in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.Hematol Oncol Stem Cell Ther. 2010; 3: 174-178
- Clinical and economic burden of infused iron chelation therapy in the United States.Transfusion. 2007; 47: 1820-1829
- Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.J Clin Pharm Ther. 2016; 41: 59-63
- Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.Am J Hematol. 2019; 94: E96-E99
- Survival in thalassaemia major patients.Circ J. 2006; 70: 1037-1042
- Results of long-term iron chelating therapy.Acta Haematol. 1996; 95: 26-36
- Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions: a long-term retrospective study (40 years) in a tertiary care center in Italy.Mediterr J Hematol Infect Dis. 2016; 8: e2016022
- The effect of iron chelation therapy on overall survival in sickle cell disease and beta-thalassemia: a systematic review.Am J Hematol. 2018; 93: 943-952
- Hepatitis C in patients with beta-thalassemia major. A single-centre experience.Ann Hematol. 2013; 92: 739-746
- Risk factors for death in patients with beta-thalassemia major: results of a case-control study.Haematologica. 2006; 91: 1420-1421
- Morbidities and mortality in transfusion-dependent Beta-thalassemia patients (single-center experience).Pediatr Hematol Oncol. 2013; 30: 93-103
- An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.BMC Clin Pharmacol. 2002; 2: 3
- Iron chelation adherence to deferoxamine and deferasirox in thalassemia.Am J Hematol. 2011; 86: 433-436
- Adherence to long-term therapies: evidence for action.J Nurs Scholarsh. 2003; 35: 207
- Beliefs about chelation among thalassemia patients. Research Support.Extramural Health Qual Life Outcomes. 2012; 10: 148
- Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia.Front Pediatr. 2022; 10: 951947
- Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients.Pharm Pract (Granada). 2022; 20: 2570
- Relationship among chelator adherence, change in chelators, and quality of life in thalassemia.Qual Life Res. 2014; 23: 2277-2288
- Behavioral contracting to improve adherence in patients with thalassemia.J Pediatr Nurs. 1993; 8: 106-111
- Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohort.Am J Hematol. 2010; 85: 802-805
- Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.Health Qual Life Outcomes. 2018; 16: 216
- Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.Curr Med Res Opin. 2018; 34: 1959-1966
- Adherence to iron chelation therapy with deferasirox formulations among patients with sickle cell disease and beta-thalassemia.J Natl Med Assoc. 2021; 113: 170-176
- Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.Lancet Haematol. 2020; 7: e469-e478
- The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.Br J Haematol. 2022; 197: e12-e15
- A study to assess and improve adherence to iron chelation therapy in transfusion-dependent thalassemia patients.Hemoglobin. 2021; 45: 171-174
- Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.Cochrane Database Syst Rev. 2019; 6: CD012900
- Impact of a transition program with navigator on loss to follow-up, medication adherence, and appointment attendance in hemoglobinopathies.Pediatr Blood Cancer. 2019; 66: e27781
- Deferasirox pharmacokinetics in patients with adequate versus inadequate response.Blood. 2009; 114: 4009-4013
- Effect of transfusional iron intake on response to chelation therapy in {beta}-thalassemia major.Blood. 2008; 111: 583-587
- Population pharmacokinetics of deferiprone in healthy subjects.Br J Clin Pharmacol. 2014; 78: 1397-1406
- Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.Br J Clin Pharmacol. 2017; 83: 593-602
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.Lancet. 2003; 361: 1597-1602
- Evaluation of pharmacokinetics and pharmacodynamics of deferasirox in pediatric patients.Pharmaceutics. 2021; 13: 1238
- Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Pharmacogenomics J. 2015; 15: 263-271
- Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Pharmacogenomics. 2017; 18: 539-554
- Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.Sci Rep. 2021; 11: 12581
- Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.Am J Hematol. 2019; 94: E15-E17
- Long-term effectiveness, safety, and tolerability of twice-daily dosing with deferasirox in children with transfusion-dependent thalassemias unresponsive to standard once-daily dosing.Mediterr J Hematol Infect Dis. 2021; 13: e2021065
- Evaluation of efficacy, safety, and satisfaction taking deferasirox twice daily versus once daily in patients with transfusion-dependent thalassemia.J Pediatr Hematol Oncol. 2020; 42: 23-26
- Efficacy and tolerability of twice-daily dosing schedule of deferasirox in transfusion-dependent paediatric beta-thalassaemia patients: a randomized controlled study.J Pharm Pract. 2022; 27 (8971900211038301)
- Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.Blood Cells Mol Dis. 2013; 51: 96-97
- Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia.J Allergy Clin Immunol. 1996; 97: 127-128
- Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.J Med Assoc Thai. 2014; 97: S217-S222
- Deferiprone-induced agranulocytosis: 20 years of clinical observations.Am J Hematol. 2016; 91: 1026-1031
Ferriprox Prescribing Information. 2021.
- Perforated duodenal ulcer associated with deferasirox in a child with beta-thalassemia major.Hemoglobin. 2021; 45: 335-337
- Drug-induced duodenal perforation in the paediatric patient with thalassemia major, an unreported side effect of iron- chelating agent: A case report.J Pak Med Assoc. 2022; 72: 1441-1443
- Perforated duodenal ulcer: a rare complication of deferasirox in children.Indian J Pharmacol. 2013; 45: 293-294
- Gastric ulcer in a child treated with deferasirox.Pharm World Sci. 2010; 32: 112-113
- Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience.Pediatr Hematol Oncol. 2021; 38: 555-563
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.Blood. 2006; 107: 3455-3462
- Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Haematologica. 2010; 95: 557-566
- Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.J Pediatr Hematol Oncol. 2010; 32: 525-526
- Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload.Vox Sang. 2021; 116: 793-797
Jadenu Prescribing Information. 7/2020 2020.
- Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.Am J Hematol. 1993; 42: 81-85
- Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.Br J Haematol. 2000; 110: 971-977
- Correlation Between Serum Ferritin and Viral Hepatitis in Thalassemia Patients.Hemoglobin. 2021; 45: 175-179
- Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload.J Clin Pathol. 1982; 35: 487-491
- Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.Am J Hematol. 2014; 89: 391-394
- Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.Eur J Haematol. 2017; 98: 280-288
- Treatment patterns and costs of transfusion and chelation in commercially-insured and Medicaid patients with transfusion-dependent beta thalassemia.Blood. 2017; 130: 5635
- ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.Eur J Clin Pharmacol. 2020; 76: 51-59
- Desferrioxamine ototoxicity:evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.Br J Haematol. 1989; 73: 403-409
- Growth failure and bony changes induced by deferoxamine.Am J Pediatr Hematol Oncol. 1992; 14: 48-56
- Role of pharmacogenetics on deferasirox AUC and efficacy.Pharmacogenetics. 2016; 17: 571-582
- Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia:incidnec and predisposing factors.Clin Infect Dis. 1998; 27: 1362-1366
- Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.Hemoglobin. 2009; 33: 352-360
- Pulmonary syndrome in patients with thalassemia major recieiving intravenous deferoxamine infusions.Am J Dis Child. 1990; 144: 565-569
- Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.J Pediatr Hematol Oncol. 1997; 19: 139-141
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
